<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37667978</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2045-7634</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>18</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cancer medicine</Title><ISOAbbreviation>Cancer Med</ISOAbbreviation></Journal><ArticleTitle>Effectiveness and safety of CD22 and CD19 dual-targeting chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell malignancies: A meta-analysis.</ArticleTitle><Pagination><StartPage>18767</StartPage><EndPage>18785</EndPage><MedlinePgn>18767-18785</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cam4.6497</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The efficacy of CD22 or CD19 chimeric antigen receptor T (CAR-T) cells in the management of acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) was observed. Because antigen loss and lack of CAR-T-cell persistence are the leading causes of progressive disease following single-antigen targeting, we evaluated CD22/CD19 dual-targeting CAR-T-cell therapy efficacy and safety in relapsed/refractory B-cell malignancies.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Web of Science, PubMed, Cochrane, and Embase databases were searched until July 2022. Patients confirmed with any relapsed/refractory B-cell hematological malignancies were included regardless of age, gender, or ethnicity, receiving CD22 and CD19-dual-targeting CAR-T-cell therapy. The studies conducted on patients with coexisting other cancer were excluded. We used random-effect models to explore the outcome, and heterogeneity was investigated by subgroup analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fourteen studies (405 patients) were included. The pooled overall response (OR) and complete remission (CR) were 97% and 93%, respectively, for ALL patients. The 1-year proportions of overall survival (OS) and progression-free survival (PFS) were 70% and 49%, respectively. For NHL, OR occurred in 85% of patients, and 57% experienced CR. The results illustrated that the 1-year OS and 1-year PFS were 77% and 65%, respectively. The subgroup analysis showed that the dual-targeting modality achieved higher CR in the following cases: coadministration of CD22/CD19-CAR-T&#x2009;cells and third-generation CAR-T cells combined with ASCT and BEAM pretreatment. The ALL and NHL groups seemed similar in treatment-related toxicity: all grade cytokine release syndrome (CRS), severe CRS, and neurotoxicity occurred in 86%, 7%, and 12% of patients, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our meta-analysis demonstrated that the CD22/CD19 dual-targeting CAR-T-cell strategy has high efficiency with tolerable adverse effects in B-cell malignancies.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Cancer Medicine published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Thi Thuy</ForeName><Initials>TT</Initials><Identifier Source="ORCID">0000-0002-5050-574X</Identifier><AffiliationInfo><Affiliation>International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Hue University of Medicine and Pharmacy, Hue University, Hue, Vietnam.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thanh Nhu</LastName><ForeName>Nguyen</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1636-6061</Identifier><AffiliationInfo><Affiliation>International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chia-Ling</ForeName><Initials>CL</Initials><Identifier Source="ORCID">0000-0003-2161-4362</Identifier><AffiliationInfo><Affiliation>School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chiou-Feng</ForeName><Initials>CF</Initials><Identifier Source="ORCID">0000-0003-4396-6086</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Core Laboratory of Immune Monitoring, Office of Research &amp; Development, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOST110-2320-B038-064-MY3</GrantID><Agency>Ministry of Science and Technology, Taiwan</Agency><Country/></Grant><Grant><GrantID>MOST111-2314-B038-120-MY3</GrantID><Agency>Ministry of Science and Technology, Taiwan</Agency><Country/></Grant><Grant><GrantID>MOST111-2320-B038-012</GrantID><Agency>Ministry of Science and Technology, Taiwan</Agency><Country/></Grant><Grant><GrantID>MOST111-2327-B006-005</GrantID><Agency>Ministry of Science and Technology, Taiwan</Agency><Country/></Grant><Grant><GrantID>TMU-MSD A-111-112</GrantID><Agency>The industry-academia cooperation program</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Med</MedlineTA><NlmUniqueID>101595310</NlmUniqueID><ISSNLinking>2045-7634</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B cell malignancies</Keyword><Keyword MajorTopicYN="N">chimeric antigen receptor T (CAR-T) therapy</Keyword><Keyword MajorTopicYN="N">dual-targeting</Keyword><Keyword MajorTopicYN="N">efficacy</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList><CoiStatement>The authors declare without conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>5</Day><Hour>5</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37667978</ArticleId><ArticleId IdType="pmc">PMC10557829</ArticleId><ArticleId IdType="doi">10.1002/cam4.6497</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singh AK, McGuirk JP. CAR T cells: continuation in a revolution of immunotherapy. Lancet Oncol. 2020;21(3):e168&#x2010;e178.</Citation><ArticleIdList><ArticleId IdType="pubmed">32135120</ArticleId></ArticleIdList></Reference><Reference><Citation>Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor&#x2010;modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509&#x2010;1518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4058440</ArticleId><ArticleId IdType="pubmed">23527958</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DW, Kochenderfer JN, Stetler&#x2010;Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose&#x2010;escalation trial. Lancet (London, England). 2015;385(9967):517&#x2010;528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7065359</ArticleId><ArticleId IdType="pubmed">25319501</ArticleId></ArticleIdList></Reference><Reference><Citation>Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507&#x2010;1517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4267531</ArticleId><ArticleId IdType="pubmed">25317870</ArticleId></ArticleIdList></Reference><Reference><Citation>Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T&#x2010;cell therapy in refractory large B&#x2010;cell lymphoma. N Engl J Med. 2017;377(26):2531&#x2010;2544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5882485</ArticleId><ArticleId IdType="pubmed">29226797</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B&#x2010;cell lymphoma. N Engl J Med. 2019;380(1):45&#x2010;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">30501490</ArticleId></ArticleIdList></Reference><Reference><Citation>Locke FL, Ghobadi A, Jacobson CA, et al. Long&#x2010;term safety and activity of axicabtagene ciloleucel in refractory large B&#x2010;cell lymphoma (ZUMA&#x2010;1): a single&#x2010;arm, multicentre, phase 1&#x2010;2 trial. Lancet Oncol. 2019;20(1):31&#x2010;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6733402</ArticleId><ArticleId IdType="pubmed">30518502</ArticleId></ArticleIdList></Reference><Reference><Citation>Majzner RG, Mackall CL. Tumor antigen escape from CAR T&#x2010;cell therapy. Cancer Discov. 2018;8(10):1219&#x2010;1226.</Citation><ArticleIdList><ArticleId IdType="pubmed">30135176</ArticleId></ArticleIdList></Reference><Reference><Citation>Orlando EJ, Han X, Tribouley C, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24(10):1504&#x2010;1506.</Citation><ArticleIdList><ArticleId IdType="pubmed">30275569</ArticleId></ArticleIdList></Reference><Reference><Citation>Fry TJ, Shah NN, Orentas RJ, et al. CD22&#x2010;targeted CAR T cells induce remission in B&#x2010;ALL that is naive or resistant to CD19&#x2010;targeted CAR immunotherapy. Nat Med. 2018;24(1):20&#x2010;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5774642</ArticleId><ArticleId IdType="pubmed">29155426</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan J, Niu Q, Deng B, et al. CD22 CAR T&#x2010;cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia. 2019;33(12):2854&#x2010;2866.</Citation><ArticleIdList><ArticleId IdType="pubmed">31110217</ArticleId></ArticleIdList></Reference><Reference><Citation>Bielamowicz K, Fousek K, Byrd TT, et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol. 2018;20(4):506&#x2010;518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909636</ArticleId><ArticleId IdType="pubmed">29016929</ArticleId></ArticleIdList></Reference><Reference><Citation>Choe JH, Watchmaker PB, Simic MS, et al. SynNotch&#x2010;CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021;13(591):eabe7378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362330</ArticleId><ArticleId IdType="pubmed">33910979</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah NN, Maatman T, Hari P, Johnson B. Multi targeted CAR&#x2010;T Cell therapies for B&#x2010;cell malignancies. Front Oncol. 2019;9:146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6423158</ArticleId><ArticleId IdType="pubmed">30915277</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokalaki E, Ma B, Ferrari M, et al. Dual targeting of CD19 and CD22 against B&#x2010;ALL using a novel high&#x2010;sensitivity aCD22 CAR. Mol Ther. 2023;31(7):2089&#x2010;2104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10362402</ArticleId><ArticleId IdType="pubmed">36945773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghorashian S, Lucchini G, Richardson R, et al. Dual antigen targeting with Co&#x2010;transduced CD19/22 CAR T cells may prevent antigen&#x2010;negative relapse after CAR T cell therapy for relapsed/refractory ALL. Blood. 2022;140(Supplement 1):10352&#x2010;10354.</Citation></Reference><Reference><Citation>Awasthi R, Pacaud L, Waldron E, et al. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Adv. 2020;4(3):560&#x2010;572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7013261</ArticleId><ArticleId IdType="pubmed">32045475</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller KT, Waldron E, Grupp SA, et al. Clinical pharmacology of Tisagenlecleucel in B&#x2010;cell acute lymphoblastic leukemia. Clin Cancer Res. 2018;24(24):6175&#x2010;6184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7433345</ArticleId><ArticleId IdType="pubmed">30190371</ArticleId></ArticleIdList></Reference><Reference><Citation>Riaz IB, Zahid U, Kamal MU, et al. Anti&#x2010;CD 19 and anti&#x2010;CD 20 CAR&#x2010;modified T cells for B&#x2010;cell malignancies: a systematic review and meta&#x2010;analysis. Immunotherapy. 2017;9(12):979&#x2010;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6040074</ArticleId><ArticleId IdType="pubmed">28971751</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H, Luo Y, Zhu S, et al. The efficacy and safety of anti&#x2010;CD19/CD20 chimeric antigen receptor&#x2010; T cells immunotherapy in relapsed or refractory B&#x2010;cell malignancies:a meta&#x2010;analysis. BMC Cancer. 2018;18(1):929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6158876</ArticleId><ArticleId IdType="pubmed">30257649</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor&#x2010;modified T cells in lymphoma patients. J Clin Invest. 2011;121(5):1822&#x2010;1826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083795</ArticleId><ArticleId IdType="pubmed">21540550</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non&#x2010;Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059&#x2010;3068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4979083</ArticleId><ArticleId IdType="pubmed">25113753</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH, Rivi&#xe8;re I, Gonen M, et al. Long&#x2010;term follow&#x2010;up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449&#x2010;459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6637939</ArticleId><ArticleId IdType="pubmed">29385376</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dongen JJ, van der Velden VH, Br&#xfc;ggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125(26):3996&#x2010;4009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4490298</ArticleId><ArticleId IdType="pubmed">25999452</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625&#x2010;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">30592986</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018;11(1):35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833070</ArticleId><ArticleId IdType="pubmed">29499750</ArticleId></ArticleIdList></Reference><Reference><Citation>Health UDo, text HSJBtc National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 403; 2010. 2019(5):6&#x2013;14.</Citation></Reference><Reference><Citation>Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non&#x2010;randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712&#x2010;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">12956787</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Li J, Zhang X, et al. Prognostic value of radiomic features of 18F&#x2010;FDG PET/CT in patients with B&#x2010;cell lymphoma treated with CD19/CD22 dual&#x2010;targeted chimeric antigen receptor T cells. Frontiers Oncology. 2022;12:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8858981</ArticleId><ArticleId IdType="pubmed">35198451</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel JY, Patel S, Muffly L, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021;27(8):1419&#x2010;1431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8363505</ArticleId><ArticleId IdType="pubmed">34312556</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Xiao Y, Wang N, et al. CD19/CD22 chimeric antigen receptor T cell cocktail therapy following autologous transplantation in patients with relapsed/refractory aggressive B cell lymphomas. Transplant Cell Ther. 2021;27(11):910. e1&#x2010;e11.</Citation><ArticleIdList><ArticleId IdType="pubmed">34425260</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordoba S, Onuoha S, Thomas S, et al. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Nat Med. 2021;27(10):1797&#x2010;1805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8516648</ArticleId><ArticleId IdType="pubmed">34642489</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai H, Wu Z, Jia H, et al. Bispecific CAR&#x2010;T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020;13(1):1&#x2010;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7126394</ArticleId><ArticleId IdType="pubmed">32245502</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Zhou Y, Zhang M, et al. CRISPR/Cas9&#x2010;engineered universal CD19/CD22 dual&#x2010;targeted CAR&#x2010;T cell therapy for relapsed/refractory B&#x2010;cell acute lymphoblastic leukemia. Clin Cancer Res. 2021;27(10):2764&#x2010;2772.</Citation><ArticleIdList><ArticleId IdType="pubmed">33627493</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Li S, Wang Y, et al. A novel and efficient CD22 CAR&#x2010;T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR&#x2010;T treatment as a sequential therapy. Exp Hematol Oncol. 2022;11(1):15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8939233</ArticleId><ArticleId IdType="pubmed">35317863</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J, Xiao M, Mao Z, et al. Outcome of aggressive B&#x2010;cell lymphoma with TP53 alterations administered with CAR T&#x2010;cell cocktail alone or in combination with ASCT. Signal Transduct Target Ther. 2022;7(1):101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8995369</ArticleId><ArticleId IdType="pubmed">35399106</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Deng B, Yin Z, et al. Combination of CD19 and CD22 CAR&#x2010;T cell therapy in relapsed B&#x2010;cell acute lymphoblastic leukemia after allogeneic transplantation. Am J Hematol. 2021;96(6):671&#x2010;679.</Citation><ArticleIdList><ArticleId IdType="pubmed">33725422</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N, Hu X, Cao W, et al. Efficacy and safety of CAR19/22 T&#x2010;cell cocktail therapy in patients with refractory/relapsed B&#x2010;cell malignancies. Blood. 2020;135(1):17&#x2010;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">31697824</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei G, Zhang Y, Zhao H, et al. CD19/CD22 dual&#x2010;targeted car t&#x2010;cell therapy for relapsed/refractory aggressive b&#x2010;cell lymphoma: a safety and efficacy study. Cancer Immunol Res. 2021;9(9):1061&#x2010;1070.</Citation><ArticleIdList><ArticleId IdType="pubmed">34290048</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng C, Cheng J, Li T, et al. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T&#x2010;cell therapy in patients with relapsed/refractory aggressive B&#x2010;cell lymphoma involving the gastrointestinal tract. Cytotherapy. 2020;22(3):166&#x2010;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">32063474</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Li J, Lou X, et al. A prospective investigation of bispecific CD19/22 CAR T cell therapy in patients with relapsed or refractory B cell non&#x2010;Hodgkin lymphoma. Front Oncol. 2021;11:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8185372</ArticleId><ArticleId IdType="pubmed">34113569</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Meng F, Cao Y, et al. Sequential CD19/22 CAR T&#x2010;cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma. Blood Cancer J. 2021;11(7):131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8282870</ArticleId><ArticleId IdType="pubmed">34267187</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassine F, Iqbal M, Murthy H, Kharfan&#x2010;Dabaja MA, Chavez JC. Real world experience of approved chimeric antigen receptor T&#x2010;cell therapies outside of clinical trials. Curr Res Transl Med. 2020;68(4):159&#x2010;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">32811793</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaglowski S, Hu Z&#x2010;H, Zhang Y, et al. Tisagenlecleucel chimeric antigen receptor (CAR) T&#x2010;cell therapy for adults with diffuse large B&#x2010;cell lymphoma (DLBCL): real world experience from the Center for International Blood &amp; Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry. Blood. 2019;134:766.</Citation></Reference><Reference><Citation>Aamir S, Anwar MY, Khalid F, Khan SI, Ali MA, Khattak ZE. Systematic review and meta&#x2010;analysis of CD19&#x2010;specific CAR&#x2010;T cell therapy in relapsed/refractory acute lymphoblastic leukemia in the pediatric and young adult population: safety and efficacy outcomes. Clin Lymphoma Myeloma Leuk. 2021;21(4):e334&#x2010;e347.</Citation><ArticleIdList><ArticleId IdType="pubmed">33573914</ArticleId></ArticleIdList></Reference><Reference><Citation>Grover P, Veilleux O, Tian L, et al. Chimeric antigen receptor T&#x2010;cell therapy in adults with B&#x2010;cell acute lymphoblastic leukemia. Blood Adv. 2022;6(5):1608&#x2010;1618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8905689</ArticleId><ArticleId IdType="pubmed">34610109</ArticleId></ArticleIdList></Reference><Reference><Citation>Anagnostou T, Riaz IB, Hashmi SK, Murad MH, Kenderian SS. Anti&#x2010;CD19 chimeric antigen receptor T&#x2010;cell therapy in acute lymphocytic leukaemia: a systematic review and meta&#x2010;analysis. Lancet Haematol. 2020;7(11):e816&#x2010;e826.</Citation><ArticleIdList><ArticleId IdType="pubmed">33091355</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X&#x2010;H, Zhang X&#x2010;Y, Dong Q&#x2010;Q, Chen F, Yang S&#x2010;B, Li W&#x2010;B. Efficacy and safety of chimeric antigen receptor&#x2010;T cells in the treatment of B cell lymphoma: a systematic review and meta&#x2010;analysis. Chin Med J. 2020;133(1):74&#x2010;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7028209</ArticleId><ArticleId IdType="pubmed">31923107</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T&#x2010;cell therapy. Mol Ther Oncolytics. 2016;3:16011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5008265</ArticleId><ArticleId IdType="pubmed">27626062</ArticleId></ArticleIdList></Reference><Reference><Citation>Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy In vivo. Mol Ther. 2009;17(8):1453&#x2010;1464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2805264</ArticleId><ArticleId IdType="pubmed">19384291</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkozy C, Sehn LH. Management of relapsed/refractory DLBCL. Best Pract Res Clin Haematol. 2018;31(3):209&#x2010;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">30213390</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauter CS, Senechal B, Rivi&#xe8;re I, et al. CD19 CAR T cells following autologous transplantation in poor&#x2010;risk relapsed and refractory B&#x2010;cell non&#x2010;Hodgkin lymphoma. Blood. 2019;134(7):626&#x2010;635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6695562</ArticleId><ArticleId IdType="pubmed">31262783</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Gao L, Wang Y, et al. Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B&#x2010;cell lymphoma. Immunotherapy. 2020;12(13):997&#x2010;1006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7546158</ArticleId><ArticleId IdType="pubmed">32752910</ArticleId></ArticleIdList></Reference><Reference><Citation>Neelapu SS, Locke FL, Bartlett NL, et al. Long&#x2010;term follow&#x2010;up ZUMA&#x2010;1: a pivotal trial of axicabtagene ciloleucel (Axi&#x2010;Cel; KTE&#x2010;C19) in patients with refractory aggressive non&#x2010;Hodgkin lymphoma (NHL). Blood. 2017;130((Supplement 1)):578.</Citation></Reference><Reference><Citation>Pennisi M, Jain T, Santomasso BD, et al. Comparing CAR T&#x2010;cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 2020;4(4):676&#x2010;686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042979</ArticleId><ArticleId IdType="pubmed">32084260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5&#x2009;Years of US Food and Drug Administration approvals. JAMA Intern Med. 2015;175(12):1992&#x2010;1994.</Citation><ArticleIdList><ArticleId IdType="pubmed">26502403</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>